Navigation Links
Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
Date:8/30/2013

Oakland, CA (PRWEB) August 30, 2013

Dennis R. Hill, MD has confirmed today that he will be speaking to the American Cancer Society Man-to-Man support group on High Dose Rate Brachytherapy Tuesday, September 24, from 6:30 to 8:00pm at the Summit Campus of Alta Bates Summit Medical Center in Oakland, CA.

The Man to Man program helps men cope with prostate cancer by offering community-based education and support for patients and their family members. Part of this volunteer organization is outreach and collaboration with health care professionals. Dr. Hill has volunteered to speak for the second time in three years. His previous High Dose Rate Brachytherapy presentation was "a big hit" according to William H. Spurgeon the facilitator of the group. He also said, "We appreciate (Dr. Hill’s) time and energies to help educate our men."

Dr. Hill explains that High Dose Rate Brachytherapy is an advanced form of treatment for prostate cancer which treats the prostate with radiation from the inside out with temporary implanted catheters. It is less rigorous than surgery, less time consuming than external beam radiation, and more precise than permanent seed implant. The success rate is the same as surgery, external beam radiation and permanent seeds and there are fewer side effects according to Dr. Hill.

Dr. Hill has been doing High Dose Rate Brachytherapy exclusively since 2004. He has done over five hundred High Dose Rate Prostate Brachytherapy implants and has published scholarly articles on the subject.

His office is located at: Dennis R. Hill MD 3012 Summit Street Suite 2675 Oakland, CA 94609 510-869-8875 drh(at)dennisrhillmd(dot)com and his website is hdrprostatebrachytherapy.com, which includes a quiz to determine if a patient is a candidate for HDR Prostate Brachytherapy.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11063057.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Discusses Prostate Cancer Stage vs. Gleason Score
2. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
3. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
4. Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same
5. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
6. Paratek Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors
7. BIOPHARMA Executives Summit, 6th BSMA Annual Conference: Look Who Is Confirmed to Speak
8. Vet-Stem, Inc. Founder and CEO, Robert Harman, DVM, Invited to Speak at the Adult Stem Cell Therapy and Regenerative Medicine Conference
9. Renowned New Jersey Plastic Surgeon Dr. Fred Coville Receives Prestigious Speaking Honor
10. DunhamTrimmer's, Bill Dunham and Mark Trimmer Are Invited Speakers at the Biopesticide Conference Organized by Informa in Raleigh, NC on August 7-8, 2013
11. Vet-Stem, Inc. Founder, Robert Harman, DVM, Invited as Inspirational Speaker for the 6th Annual After the Finish Line Charity Dinner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
Breaking Biology News(10 mins):